Mark S. Cohen is a founder of Pearl Cohen Zedek Latzer Baratz, Partner, Chair of the Life Science Practice Group, and a member of the firm’s Executive Committee.
Mark’s practice focuses on patent prosecution in the pharmaceutical, chemical, biological, and medical device areas, as well as licensing and client counselling. He is well-versed in all aspects of patent prosecution, intellectual property management, strategic advice, technology assessment, commercial transactional matters, and licensing matters. His work includes management of large patent portfolios, negotiating terms, drafting agreements, and counselling start-ups. He has been involved in large due diligence matters; infringement (FTO), validity and patentability opinions; commercial transactional matters; and opposition proceedings in Europe.
Mark Cohen was a Board Member of Tarus Therapeutics, Inc, and Masthercell Global Inc. a subsidiary of Orgenesis Inc. (Nasdaq: ORGS), a manufacturer, service provider and developer of advanced cell therapies. Mark Cohen was Vice Chairman of the Board, and Chairman of the Governance and Nominating Committee of Akari Therapeutics, Plc. (NASDAQ: AKTX) an emerging biopharmaceutical company that is developing anti-complement and anti-inflammatory molecules as life-transforming treatments for a wide range of severe and orphan autoimmune and inflammatory diseases.
He has published in Nature Biotechnology and various patent trade journals. He has lectured at the Practicing Law Institute (PLI) and the American Conference Institute on general patent topics, and at other venues in the US and Europe on patent issues in the biotechnology/ pharmaceutical area. Mark also served as Editor-in-Chief of the University of Baltimore Intellectual Property Law Journal.
His clients that he represents range from start-up companies to Fortune 500 companies. He represents global corporations, as well as mid-size companies; private companies, technology transfer offices of academic institutions; fundamental institutional funds; and start-up companies in the biotechnology/biopharmaceutical/immunotherapy area.